ANTICOAGULANTS AND EPISTAXIS: A COMPARATIVE ANALYSIS OF EPISTAXIS WITH WARFARIN AND DIRECT ORAL ANTICOAGULANTS

S AZHAR; SI AHMED; A MUKHTAR; H AZHAR; A HASSAN; Z HASHIR

doi:10.54112/bcsrj.v2023i1.374

Authors

S AZHAR Department of General Medicine, Islamabad Medical and Dental College, Islamabad, Pakistan
SI AHMED Department of General Medicine, Islamabad Medical and Dental College, Islamabad, Pakistan
A MUKHTAR Department of Gynaecology, Railway General Hospital Rawalpindi, Pakistan
H AZHAR Department of Radiology, CMH Muzaffarabad, Pakistan
A HASSAN Department of Gastroenterology, Islamabad Medical and Dental College, Islamabad, Pakistan
Z HASHIR Department of General Medicine, Islamabad Medical and Dental College, Islamabad, Pakistan

DOI:

https://doi.org/10.54112/bcsrj.v2023i1.374

Keywords:

Warfarin, Direct oral anticoagulants, Epistaxis, Anticoagulation therapy, Bleeding risk, Hemorrhage Oral anticoagulants, Blood thinners

Abstract

Anticoagulant therapy prevents and treats thromboembolic occasions like profound vein thrombosis, pneumonic embolism, and stroke. Warfarin, a vitamin K bad guy, has been the standard oral anticoagulant for quite some time. The study's main objective is to find that warfarin is associated with higher rates of epistaxis compared to direct oral anticoagulants. This cross-sectional study was conducted at Islamabad Medical and Dental College, Islamabad, from January 2023 till July 2023. Data was collected from 123 patients of both genders. The study population consists of adult patients prescribed anticoagulant therapy for various indications, including atrial fibrillation, venous thromboembolism, and mechanical heart valve replacement. Patients were identified from electronic medical records at the study site. In this study, a total of 123 adult patients receiving anticoagulant therapy were included. Among them, 62 patients were prescribed warfarin, and 61 were on direct oral anticoagulants (DOACs) (rivaroxaban, dabigatran, apixaban, or edoxaban). Warfarin and DOACs demonstrated similar safety profiles regarding other bleeding events and major adverse events. It is concluded that the study found no statistically significant difference in the incidence of epistaxis between the two treatment groups. Both Warfarin and DOACs showed similar safety profiles regarding other bleeding events and major adverse events, indicating that they are generally well-tolerated options for anticoagulation therapy in this patient population.

Downloads

Download data is not yet available.

References

Bahit, M. C., Lopes, R. D., Wojdyla, D. M., Held, C., Hanna, M., Vinereanu, D., Hylek, E. M., Verheugt, F., Goto, S., and Alexander, J. H. (2017). Non-major bleeding with apixaban versus warfarin in patients with atrial fibrillation. Heart 103, 623-628.

Bola, S., Marsh, R., Braggins, S., Potter, C., and Hickey, S. (2016). Does the continuation of warfarin change management outcomes in epistaxis patients? The Journal of Laryngology & Otology 130, 256-260.

Denholm, S., Maynard, C., and Watson, H. (1993). Warfarin and epistaxis—a case controlled study. The Journal of Laryngology & Otology 107, 195-196.

Donaldson, G., Goh, K. Y., Tiwari, P., Maini, S., Ram, B., and Dwivedi, R. C. (2021). Anti-thrombotics and their impact on inpatient epistaxis management: a tertiary centre experience. Irish Journal of Medical Science (1971-), 1-9.

Douglas, C. M., Tikka, T., Broadbent, B., Calder, N., and Montgomery, J. (2018). Patterns of hospital admission in 54 501 patients with epistaxis over a 20‐year period in Scotland, UK. Clinical Otolaryngology 43, 1465-1470.

Ingason, A. B., Hreinsson, J. P., Agustsson, A. S., Lund, S. H., Rumba, E., Palsson, D. A., Reynisson, I. E., Gudmundsdottir, B. R., Onundarson, P. T., and Bjornsson, E. S. (2023). Warfarin is associated with higher rates of upper but not lower gastrointestinal bleeding compared with direct oral anticoagulants: a population-based propensity-weighted cohort study. Clinical Gastroenterology and Hepatology 21, 347-357. e10.

Kikidis, D., Tsioufis, K., Papanikolaou, V., Zerva, K., and Hantzakos, A. (2014). Is epistaxis associated with arterial hypertension? A systematic review of the literature. European Archives of Oto-Rhino-Laryngology 271, 237-243.

L’Huillier, V., Badet, C., and Tavernier, L. (2018). Epistaxis complicating treatment by anti-vitamin K and new oral anticoagulants. European Annals of Otorhinolaryngology, Head and Neck Diseases 135, 231-235.

Loo, S. Y., Dell'Aniello, S., Huiart, L., and Renoux, C. (2017). Trends in the prescription of novel oral anticoagulants in UK primary care. British journal of clinical pharmacology 83, 2096-2106.

Mehta, N., Williams, R., Smith, M., Hall, A., Hardman, J., Cheung, L., Ellis, M., Fussey, J., Lakhani, R., and McLaren, O. (2017). Can trainees design and deliver a national audit of epistaxis management? A pilot of a secure web-based audit tool and research trainee collaboratives. The Journal of Laryngology & Otology 131, 518-522.

Sauter, T., Hegazy, K., Hautz, W., Krummrey, G., Ricklin, M., Nagler, M., Borner, U., and Exadaktylos, A. (2018). Epistaxis in anticoagulated patients: Fewer hospital admissions and shorter hospital stays on rivaroxaban compared to phenprocoumon. Clinical otolaryngology 43, 103-108.

Siegal, D. M., and Crowther, M. A. (2013). Acute management of bleeding in patients on novel oral anticoagulants. European heart journal 34, 489-498.

Williams, A., Biffen, A., Pilkington, N., Arrick, L., Williams, R., Smith, M., Smith, M., and Birchall, J. (2017). Haematological factors in the management of adult epistaxis: systematic review. The Journal of Laryngology & Otology 131, 1093-1107.